eIF4A inhibitors suppress cell cycle feedback response and acquired resistance to CDK4/6 inhibition in cancer

Molecular Cancer Therapeutics
Tim KongSidong Huang

Abstract

CDK4/6 inhibitors are FDA-approved drugs for estrogen receptor-positive (ER+) breast cancer and are being evaluated to treat other tumor types including KRAS mutant non-small cell lung cancer (NSCLC). However, their clinical utility is often limited by drug resistance. Here, we sought to better understand the resistant mechanisms and help devise potential strategies to overcome this challenge. We show that treatment of CDK4/6 inhibitors in both ER+ breast cancer and KRAS mutant NSCLC cells induce feedback upregulation of cyclin D1, CDK4 and cyclin E1 mediating drug resistance. We demonstrate that rocaglates, which preferentially target translation of key cell cycle regulators, effectively suppresses this feedback upregulation induced by CDK4/6 inhibition. Consequently, combination treatment of CDK4/6 inhibitor palbociclib with the eukaryotic initiation factor (eIF) 4A inhibitor, CR-1-31-B, is synergistic in suppressing the growth of these cancer cells in vitro and in vivo. Furthermore, ER+ breast cancer and KRAS mutant NSCLC cells that acquired resistance to palbociclib after chronic drug exposure are also highly sensitive to this combination treatment strategy. Our findings reveal a novel strategy using eIF4A inhibitors to sup...Continue Reading

References

Feb 7, 1997·Cell·R M ZwijsenR J Michalides
Sep 15, 2004·Trends in Biochemical Sciences·Adrian P BrackenKristian Helin
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Sep 7, 2007·Angewandte Chemie·Baudouin GerardJohn A Porco
Jun 14, 2008·The Journal of Clinical Investigation·Marie-Eve BordeleauJerry Pelletier
Aug 1, 2014·Nature·Andrew L WolfeHans-Guido Wendel
Aug 1, 2014·Nature·Lise BoussemartStéphan Vagner
Sep 10, 2014·Proceedings of the National Academy of Sciences of the United States of America·Francis RobertJerry Pelletier
Sep 23, 2014·Biochimica Et Biophysica Acta·Jennifer Chu, Jerry Pelletier
Jan 17, 2015·Cancer Research·Jerry PelletierNahum Sonenberg
Jan 31, 2015·Nature Reviews. Drug Discovery·Uzma AsgharErik S Knudsen
Mar 7, 2015·Nature Reviews. Drug Discovery·Mamatha BhatIvan Topisirovic
Nov 21, 2015·Molecular Cancer Therapeutics·Jennifer ChuJerry Pelletier
Dec 15, 2015·Cancer Discovery·Charles J SherrGeoffrey I Shapiro
Mar 30, 2016·Cancer Research·Maria Teresa Herrera-AbreuVioleta Serra
May 23, 2017·Cancer Cell·Yiqun ZhangChad J Creighton
Nov 28, 2017·Current Opinion in Genetics & Development·Lisa M LindqvistLuc Furic
Feb 22, 2018·Oncogene·Santiago Ramon Y CajalNahum Sonenberg
May 10, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Renée de LeeuwKaren E Knudsen
Oct 23, 2018·The New England Journal of Medicine·Nicholas C TurnerMassimo Cristofanilli

❮ Previous
Next ❯

Citations

Jan 9, 2021·Cell Death & Disease·Hongsheng LiuYingyi Wang
Jan 10, 2021·Life Sciences·Sepideh MirzaeiMichael R Hamblin
Aug 4, 2021·Nature Reviews. Cancer·Lucilla FabbriStéphan Vagner
Aug 17, 2021·Frontiers in Oncology·Jinmeng ZhangXi Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.